DELIVERY ORDER
Active75N98026F00002
Department of Health and Human Services › National Institutes of Health › NATIONAL INSTITUTES OF HEALTH OLAO
$1.4M
obligated · signed 2 months ago
NINDS' DRUG MANUFACTURING AND FORMULATION PROGRAM (DMFP): SHAMLOO-SELECTIVE CB2 AGONIST; MRI RESEARCH INC:1186811 [26-000042]
Performance timeline
Start
Aug 15, 2026
Current end
Aug 14, 2030
Potential end
Aug 14, 2032
with all options
Loading status
Estimated start: Aug 14, 2031
MRIGLOBAL
Contract 75N98026F00002
UEI
HKQHNFKNKL15
Parent Company
MRIGLOBAL
Capabilities & Certifications
Headquarters Location
Congressional District: 05
Current Obligation
$1,363,408
Base + Exercised Options
$1,363,408
Total Ceiling Value
$2,534,752
Contract Type
COST PLUS FIXED FEE
Multi-Year Contract
NO
NAICS
PHARMACEUTICAL PREPARATION MANUFACTURING
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Place of Performance
Congressional District: 05
Awarding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH OLAO
Office
Funding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH NINDS
Office
Contract Vehicle
75N98026D00014
IDCDepartment of Health and Human Services
Award type: MULTIPLE AWARD
Solicitation procedures, competition exceptions, labor standards and account totals.